Biogen, Ionis to stop development of BIIB105 as treatment for ALS
Biogen and Ionis Pharmaceuticals have decided to terminate the development of BIIB105, their experimental treatment for amyotrophic…
Articles by Andrea Lobo, PhD
University of Michigan neurologist wins award for ALS research
University of Michigan neurologist Eva Feldman was recently recognized with the 2024 Sheila Essey Award for her groundbreaking research on…
Robot caregiver will help ALS patients with daily needs: Scientists
Scientists at Stony Brook University aim to create a caregiving robot assistant (CART) to help people with amyotrophic lateral…
Rural living may widen gap between early ALS symptoms, diagnosis
Having possible symptoms of amyotrophic lateral sclerosis (ALS) increases the chances of getting an ALS diagnosis by nearly five…
ETSU ALS clinic receives $75K grant to expand free care services
The Gary E. Shealy Memorial ALS Clinic in Tennessee has received a $75,000 grant from the ALS Association to support…
Phase 2 trial testing dazucorilant in ALS patients now fully enrolled
A double-blind Phase 2 clinical trial that will test Corcept Therapeutics’ oral cortisol modulator dazucorilant against a placebo in…
ALS Association, myTomorrows team up to aid clinical trial access
The ALS Association is partnering with MyTomorrows, a global health technology company, to make it easier for people…
Health Canada now reviewing Qalsody as treatment for SOD1-ALS
Health Canada is now reviewing Qalsody (tofersen) as a potential treatment for people with amyotrophic lateral sclerosis (ALS) who carry mutations in…
Coave wins grant to advance gene therapy CTx-TFEB for ALS
Coave Therapeutics has received a grant from the ALS Association to support the development of its gene therapy…
Vet drug monepantel slows ALS, MND disease progression in trial
Daily treatment with monepantel — a drug widely used in veterinary medicine — was shown to reduce the rate…